Showing results (141-150 of 308) with videos related to

Sort By:
Pageof 31
Methods and Findings in Experimental and Clinical Pharmacology|April 19, 2005
Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluidsB Oshrine, A Malinin, A Pokov, et al.
Pharmacological Research|July 1, 1997
Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factorsV L Serebruany, W R Herzog, M L Schlossberg, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|September 7, 1999
Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarctionP A Gurbel, S R Murugesan, D R Lowry, et al.
American Journal of Hematology|April 17, 1998
Plasma fibronectin during myocardial ischemia-reperfusion: effects of magnesium, diltiazem, and a novel Mac-1 inhibitorV L Serebruany, S R Solomon, W R Herzog, et al.
Clinical Therapeutics|March 18, 2008
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trialVictor L Serebruany, Alex I Malinin, Alex N Pokov, et al.
Pharmacological Research|August 6, 1999
Clopidogrel: the future choice for preventing platelet activation during coronary stenting?P A Gurbel, C M O'Connor, C C Cummings, et al.
Thrombosis Research|March 21, 2006
Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?Victor Serebruany, Alex Malinin, Alex Pokov, et al.
Expert Review of Neurotherapeutics|November 14, 2015
Vorapaxar for secondary stroke prevention: perspectives and obstaclesVictor L Serebruany, Moo Hyun Kim, Seth D Fortmann, et al.
Thrombosis and Haemostasis|November 13, 2015
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challengesVictor L Serebruany, Vasily Cherepanov, Hector A Cabrera-Fuentes, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and UnderreportingVictor L Serebruany, Ales Tomek, Moo Hyun Kim, et al.
Pageof 31